In a retrospective study, outcomes of 44 patients with metastatic EGFR-mutated NSCLC who received osimertinib plus chemotherapy, including platinum doublets or single agents, as second-line or later therapy, were analyzed. Here, EGFR is linked to non-small cell lung carcinoma.